BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23890169)

  • 1. [Limb perfusion in soft tissue sarcomas: twenty years of experience].
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Pras EB; Suurmeijer A; Hoekstra HJ
    Ned Tijdschr Geneeskd; 2013; 157(30):A6148. PubMed ID: 23890169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
    Cherix S; Speiser M; Matter M; Raffoul W; Liénard D; Theumann N; Mouhsine E; Mirimanoff RO; Leyvraz S; Lejeune FJ; Leyvraz PF
    J Surg Oncol; 2008 Sep; 98(3):148-55. PubMed ID: 18668638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
    Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
    Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients?
    Deroose JP; Burger JW; van Geel AN; den Bakker MA; de Jong JS; Eggermont AM; Verhoef C
    Ann Surg Oncol; 2011 Feb; 18(2):321-7. PubMed ID: 21049306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of isolated limb perfusion in advanced soft tissue sarcoma of the extremity.
    Olofsson R; Bergh P; Berlin O; Engström K; Gunterberg B; Hansson M; Lindnér P; Mattsson J
    Ann Surg Oncol; 2012 Jun; 19(6):1800-7. PubMed ID: 22219068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients.
    Deroose JP; van Geel AN; Burger JW; Eggermont AM; Verhoef C
    J Surg Oncol; 2012 May; 105(6):563-9. PubMed ID: 22020863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with irresectable soft tissue tumors.
    Vrouenraets BC; Keus RB; Nieweg OE; Kroon BB
    J Surg Oncol; 1997 Jun; 65(2):88-94. PubMed ID: 9209519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study.
    Huis In 't Veld EA; Grünhagen DJ; Verhoef C; Smith HG; van Akkooi ACJ; Jones R; van Coevorden F; Hayes AJ; van Houdt WJ
    Eur J Cancer; 2017 Nov; 85():114-121. PubMed ID: 28918185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF dose reduction and shortening of duration of isolated limb perfusion for locally advanced soft tissue sarcoma of the extremities is safe and effective in terms of long-term patient outcome.
    Hoven-Gondrie ML; Bastiaannet E; van Ginkel RJ; Suurmeijer AJ; Hoekstra HJ
    J Surg Oncol; 2011 Jun; 103(7):648-55. PubMed ID: 21337343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
    Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
    J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity.
    Hoven-Gondrie ML; Thijssens KM; Van den Dungen JJ; Loonstra J; van Ginkel RJ; Hoekstra HJ
    Ann Surg Oncol; 2007 Jul; 14(7):2105-12. PubMed ID: 17457649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncological outcome of primary non-metastatic soft tissue sarcoma treated by neoadjuvant isolated limb perfusion and tumor resection.
    Jakob J; Tunn PU; Hayes AJ; Pilz LR; Nowak K; Hohenberger P
    J Surg Oncol; 2014 Jun; 109(8):786-90. PubMed ID: 24619722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic isolated limb perfusion with tumour necrosis factor-alpha and melphalan as palliative limb-saving treatment in patients with locally advanced soft-tissue sarcomas of the extremities with regional or distant metastases. Is it worthwhile?
    Olieman AF; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Arch Orthop Trauma Surg; 1998; 118(1-2):70-4. PubMed ID: 9833110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
    Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
    Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and efficacy of external beam radiotherapy after hyperthermic isolated limb perfusion with TNF-alpha and melphalan for limb-saving treatment in locally advanced extremity soft-tissue sarcoma.
    Olieman AF; Pras E; van Ginkel RJ; Molenaar WM; Schraffordt Koops H; Hoekstra HJ
    Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):807-14. PubMed ID: 9531364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
    Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
    Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of isolated hyperthermic extremity perfusion in soft tissue sarcomas within the scope of a multimodality treatment concept].
    Schwarzbach M; Lehnert T; Willeke F; Hinz U; Herfarth C
    Chirurg; 1996 Dec; 67(12):1237-43. PubMed ID: 9081786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncological outcomes of isolated limb perfusion and neo-adjuvant radiotherapy in soft tissue sarcoma patients - A nationwide multicenter study.
    van Praag VM; Fiocco M; Bleckman RF; van Houdt WJ; Haas RLM; Verhoef C; Grunhagen DJ; van Ginkel RJ; Bonenkamp JJ; van de Sande MAJ
    Eur J Surg Oncol; 2023 Feb; 49(2):339-344. PubMed ID: 36085118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.